A trial of a vaccine called DCVax-L for glioblastoma
Cancer type:
Status:
Phase:
This trial looked at personalised vaccines to treat a type of brain tumour called glioblastoma. It was for people who had recently been diagnosed and were due to have surgery.
More about this trial
Doctors often treat glioblastoma (GBM) with surgery, radiotherapy and chemotherapy. They wanted to see if having a vaccine called DCVax-L helps.
DCVax-L is a type of immunotherapy called a 
. They use immune cells called dendritic cells to make the vaccine. The researchers mix these cells with proteins from brain tumour cells.
Doctors hoped DCVax-L would help the immune system to recognise and kill brain tumour cells.
People in this trial were put into a treatment group at random. Some had the chemotherapy drug temozolomide and DCVax-L. And some had temozolomide and a dummy drug (placebo).
The main aim of the trial was to see if DCVax-L helps people with glioblastoma live longer.
Summary of results
Summary of results
As part of our editorial policy, any trial information we write is checked externally before we put it on our website. The research team have published some results for this trial. But we have been unable to find anyone involved with the trial to check the summary for us.
This means we are not able to include a plain English summary of the results on this page.
More information
There is more information about this trial in the links to the medical journal papers below.
Please note, the information we link to here is not in plain English. It has been written for health care professionals and researchers.
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma
L. Liau and others
JAMA Oncology, 2023. Volume 9, issue 1, pages 112 – 121.
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
L Liau and others
Journal of Transitional Medicine, 2018. Volume 16, article number 142.
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Prof Keyoumars Ashkan
Supported by
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
Northwest Biotherapeutics
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
